Author： Doyle Scott Lloyd Andrew
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.30, Iss.12, 2012-12, pp. : 1133-1143
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
By Vijgen Sylvia M.C. Hoogendoorn Mirjam Baan Caroline A. G. Ardine de Wit Limburg Wien Feenstra Talitha L.
PharmacoEconomics, Vol. 24, Iss. 5, 2006-01 ,pp. :
Access to resources
Recommend
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
Drug Safety, Vol. 20, Iss. 6, 1999-06 ,pp. :
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. :
Troglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Drugs, Vol. 57, Iss. 3, 1999-03 ,pp. :